Biocon targets emerging, developed markets with biosimilars

Biocon had launched its biosimilar Trastuzumab in India in 2014 as CANMAb for treating metastatic breast cancer.

"We expect the clinical progress in biosimilars and novels to augur well for the company, going forward," she added.

Commenting on market opportunities, Shaw said: "Emerging markets present an important opportunity for Biocon. We are already addressing the large need for affordable insulin therapy in India and several emerging markets through our generic recombinant human Insulin (rh- Insulin) and Insulin Glargine."

She further said: "We are working on enhancing the emerging markets footprint for our biosimilars even as the clinical development of these molecules progresses in developed markets."

The company already has marketing approvals in over 60 countries for rh-insulin and in over 20 countries for insulin Glargine, she added.

Earlier during the year, Biocon had received regulatory approval in Mexico for insulin Glargine, which was the first product to be approved as per the biocomparable guidelines defined by the Mexican health authority in 2012.

Patient recruitment in the insulin Glargine global phase-III trials were completed in the first quarter of this fiscal.

Patient recruitment for multi-centric global phase-III clinical trials for Pegfilgrastim and Trastuzumab are nearing completion, Biocon said.

"Global Phase-III clinical trial for Adalimumab is progressing well across multiple sites. Global Phase-I PK study for Bevacizumab is approaching completion while the ROW focused Phase-III trial is advancing as per plan," the company added.